Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02557971 · ClinicalTrials.gov registry record
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 315
- Enrollment target
NCT02557971 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 315 participants.
The verdict
NCT02557971 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 315 participants
- Enrollment target
Study Summary
This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.
Interventions
- DRUG onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02557971
The ClinicalTrials.gov registry entry for NCT02557971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT02557971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02557971 about?
NCT02557971 is a clinical study titled "Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder". This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary ...
What is the current status of trial NCT02557971?
This trial is currently completed. The enrollment target is 315 participants. The study started on 2015-08. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02557971?
The interventions under investigation include: onabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02557971?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.